4.2 Article

Green Tea Polyphenol Epigallocatechin-3-Gallate Inhibits TNF-α-Induced Production of Monocyte Chemoattractant Protein-1 in Human Umbilical Vein Endothelial Cells

期刊

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 33, 期 5, 页码 1349-1358

出版社

KARGER
DOI: 10.1159/000358702

关键词

Green tea; Epigallocatechin-3-gallate; Monocyte chemoattractant protein-1; Human umbilical vein endothelial cells

资金

  1. National Natural Science Foundation of China [81270255, 30971254]
  2. Science and Technological Innovation Group of Jiangsu Higher Education Institution Qing-Lan Project [JX2161015030]
  3. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

向作者/读者索取更多资源

Aims: Epigallocatechin-3-gallate (EGCG), a major catechin found in green tea, displays a variety of pharmacological properties and recently received attention as a prospective dietary intervention in cardiovascular diseases (CVD). This study was conducted to test the hypothesis that EGCG was able to inhibit tumor necrosis factor-a (TNF-alpha)-induced production of monocyte chemoattractant protein-1 (MCP-1) in human umbilical vein endothelial cells (HUVECs) and investigated the underlying molecular mechanisms. Methods: The inhibitory effect of EGCG on TNF-alpha-induced expression of MCP-1 was measured using ELISA and RT-qPCR. The effect of EGCG on TNF-a-induced nuclear factor-kappa B (NF-kappa B) activation was investigated by western blot and luciferase assays. Monocyte adhesion assay was detected by microscope. Results: EGCG significantly suppressed the TNF-a-induced protein and mRNA expression of MCP-1. Investigation of the mechanism suggested that EGCG suppressed the TNF-alpha-mediated NF-kappa B activation. In addition, the 67-kD laminin receptor (67LR) was involved in EGCG-mediated suppression of MCP-1 generation. Furthermore, EGCG potently inhibited monocyte adhesion to activated HUVECs. Conclusion: EGCG suppresses TNF-alpha-induced MCP-1 expression in HUVECs. This effect was mediated by 67LR and was via the inhibition of NF-kappa B activation. Our results demonstrated that EGCG might be a possible medicine for CVD prevention and treatment. Copyright (C) 2014 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据